

Global Drugs for Herpes Labialis (Oral Herpes) Market Analysis and Forecast 2024-2030

<https://marketpublishers.com/r/GC1598F7BEEAEN.html>

Date: April 2024

Pages: 200

Price: US\$ 4,950.00 (Single User License)

ID: GC1598F7BEEAEN

Abstracts

Summary

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.

According to APO Research, The global Drugs for Herpes Labialis (Oral Herpes) market is projected to grow from US\$ million in 2024 to US\$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Drugs for Herpes Labialis (Oral Herpes) is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Drugs for Herpes Labialis (Oral Herpes) is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Drugs for Herpes Labialis (Oral Herpes) is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Drugs for Herpes Labialis (Oral Herpes) is estimated to increase from

\$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Drugs for Herpes Labialis (Oral Herpes) include GSK, Novartis, Teva, Mylan, Cadila, Apotex, Daewoong Pharmaceutical, Livzon and Luoxin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drugs for Herpes Labialis (Oral Herpes), market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Drugs for Herpes Labialis (Oral Herpes), also provides the revenue of main regions and countries. Of the upcoming market potential for Drugs for Herpes Labialis (Oral Herpes), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for Herpes Labialis (Oral Herpes) revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Drugs for Herpes Labialis (Oral Herpes) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Drugs for Herpes Labialis (Oral Herpes) revenue, projected growth trends, production technology, application and end-user industry.

Drugs for Herpes Labialis (Oral Herpes) segment by Company

GSK

Novartis

Teva

Mylan

Cadila

Apotex

Daewoong Pharmaceutical

Livzon

Luoxin

Med shine

Bayer (Campho Phenique)

Blistex

Kelun

Hikma

Haiwang

Carmex

Cipher

Drugs for Herpes Labialis (Oral Herpes) segment by Type

Aciclovir

Valacyclovir

Famciclovir

Docosanol

Other

Drugs for Herpes Labialis (Oral Herpes) segment by Application

External Use

Oral

Injection

Drugs for Herpes Labialis (Oral Herpes) segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Herpes Labialis (Oral Herpes) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for Herpes Labialis (Oral Herpes) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Herpes Labialis (Oral Herpes).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drugs for Herpes Labialis (Oral Herpes) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drugs for Herpes Labialis (Oral Herpes) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Herpes Labialis (Oral Herpes) revenue, gross margin, and recent development, etc.

Chapter 8: North America (US & Canada) by type, by application and by country,

revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

Contents

1 MARKET OVERVIEW

- 1.1 Product Definition
- 1.2 Drugs for Herpes Labialis (Oral Herpes) Market by Type
 - 1.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Type, 2019 VS 2023 VS 2030
 - 1.2.2 Aciclovir
 - 1.2.3 Valacyclovir
 - 1.2.4 Famciclovir
 - 1.2.5 Docosanol
 - 1.2.6 Other
- 1.3 Drugs for Herpes Labialis (Oral Herpes) Market by Application
 - 1.3.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Application, 2019 VS 2023 VS 2030
 - 1.3.2 External Use
 - 1.3.3 Oral
 - 1.3.4 Injection
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives

2 DRUGS FOR HERPES LABIALIS (ORAL HERPES) MARKET DYNAMICS

- 2.1 Drugs for Herpes Labialis (Oral Herpes) Industry Trends
- 2.2 Drugs for Herpes Labialis (Oral Herpes) Industry Drivers
- 2.3 Drugs for Herpes Labialis (Oral Herpes) Industry Opportunities and Challenges
- 2.4 Drugs for Herpes Labialis (Oral Herpes) Industry Restraints

3 GLOBAL GROWTH PERSPECTIVE

- 3.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Perspective (2019-2030)
- 3.2 Global Drugs for Herpes Labialis (Oral Herpes) Growth Trends by Region
 - 3.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region: 2019 VS 2023 VS 2030
 - 3.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2019-2024)
 - 3.2.3 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2025-2030)

4 COMPETITIVE LANDSCAPE BY PLAYERS

4.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Players

4.1.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Players (2019-2024)

4.1.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Players (2019-2024)

4.1.3 Global Drugs for Herpes Labialis (Oral Herpes) Players Revenue Share Top 10 and Top 5 in 2023

4.2 Global Drugs for Herpes Labialis (Oral Herpes) Key Players Ranking, 2022 VS 2023 VS 2024

4.3 Global Drugs for Herpes Labialis (Oral Herpes) Key Players Headquarters & Area Served

4.4 Global Drugs for Herpes Labialis (Oral Herpes) Players, Product Type & Application

4.5 Global Drugs for Herpes Labialis (Oral Herpes) Players Commercialization Time

4.6 Market Competitive Analysis

4.6.1 Global Drugs for Herpes Labialis (Oral Herpes) Market CR5 and HHI

4.6.2 Global Top 5 and 10 Drugs for Herpes Labialis (Oral Herpes) Players Market Share by Revenue in 2023

4.6.3 2023 Drugs for Herpes Labialis (Oral Herpes) Tier 1, Tier 2, and Tier

5 DRUGS FOR HERPES LABIALIS (ORAL HERPES) MARKET SIZE BY TYPE

5.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019 VS 2023 VS 2030)

5.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2030)

5.3 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Type (2019-2030)

6 DRUGS FOR HERPES LABIALIS (ORAL HERPES) MARKET SIZE BY APPLICATION

6.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019 VS 2023 VS 2030)

6.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2030)

6.3 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Application (2019-2030)

7 COMPANY PROFILES

7.1 GSK

7.1.1 GSK Company Information

7.1.2 GSK Business Overview

7.1.3 GSK Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.1.4 GSK Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.1.5 GSK Recent Developments

7.2 Novartis

7.2.1 Novartis Company Information

7.2.2 Novartis Business Overview

7.2.3 Novartis Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.2.4 Novartis Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.2.5 Novartis Recent Developments

7.3 Teva

7.3.1 Teva Company Information

7.3.2 Teva Business Overview

7.3.3 Teva Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.3.4 Teva Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.3.5 Teva Recent Developments

7.4 Mylan

7.4.1 Mylan Company Information

7.4.2 Mylan Business Overview

7.4.3 Mylan Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.4.4 Mylan Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.4.5 Mylan Recent Developments

7.5 Cadila

7.5.1 Cadila Company Information

7.5.2 Cadila Business Overview

7.5.3 Cadila Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.5.4 Cadila Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.5.5 Cadila Recent Developments

7.6 Apotex

7.6.1 Apotex Company Information

7.6.2 Apotex Business Overview

7.6.3 Apotex Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.6.4 Apotex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.6.5 Apotex Recent Developments

7.7 Daewoong Pharmaceutical

7.7.1 Daewoong Pharmaceutical Company Information

7.7.2 Daewoong Pharmaceutical Business Overview

7.7.3 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.7.4 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.7.5 Daewoong Pharmaceutical Recent Developments

7.8 Livzon

7.8.1 Livzon Company Information

7.8.2 Livzon Business Overview

7.8.3 Livzon Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.8.4 Livzon Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.8.5 Livzon Recent Developments

7.9 Luoxin

7.9.1 Luoxin Company Information

7.9.2 Luoxin Business Overview

7.9.3 Luoxin Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.9.4 Luoxin Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.9.5 Luoxin Recent Developments

7.10 Med shine

7.10.1 Med shine Company Information

7.10.2 Med shine Business Overview

7.10.3 Med shine Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.10.4 Med shine Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.10.5 Med shine Recent Developments

7.11 Bayer (Campho Phenique)

7.11.1 Bayer (Campho Phenique) Company Information

7.11.2 Bayer (Campho Phenique) Business Overview

7.11.3 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.11.4 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Product

Portfolio

7.11.5 Bayer (Campho Phenique) Recent Developments

7.12 Blistex

7.12.1 Blistex Company Information

7.12.2 Blistex Business Overview

7.12.3 Blistex Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.12.4 Blistex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.12.5 Blistex Recent Developments

7.13 Kelun

7.13.1 Kelun Company Information

7.13.2 Kelun Business Overview

7.13.3 Kelun Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.13.4 Kelun Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.13.5 Kelun Recent Developments

7.14 Hikma

7.14.1 Hikma Company Information

7.14.2 Hikma Business Overview

7.14.3 Hikma Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.14.4 Hikma Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.14.5 Hikma Recent Developments

7.15 Haiwang

7.15.1 Haiwang Company Information

7.15.2 Haiwang Business Overview

7.15.3 Haiwang Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.15.4 Haiwang Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.15.5 Haiwang Recent Developments

7.16 Carmex

7.16.1 Carmex Company Information

7.16.2 Carmex Business Overview

7.16.3 Carmex Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)

7.16.4 Carmex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

7.16.5 Carmex Recent Developments

7.17 Cipher

7.17.1 Cipher Company Information

- 7.17.2 CIPHER Business Overview
- 7.17.3 CIPHER Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2019-2024)
- 7.17.4 CIPHER Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- 7.17.5 CIPHER Recent Developments

8 NORTH AMERICA

- 8.1 North America Drugs for Herpes Labialis (Oral Herpes) Revenue (2019-2030)
- 8.2 North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2030)
 - 8.2.1 North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2024)
 - 8.2.2 North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2025-2030)
- 8.3 North America Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Type (2019-2030)
- 8.4 North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2030)
 - 8.4.1 North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2024)
 - 8.4.2 North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2025-2030)
- 8.5 North America Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Application (2019-2030)
- 8.6 North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Country
 - 8.6.1 North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019 VS 2023 VS 2030)
 - 8.6.2 North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019-2024)
 - 8.6.3 North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2025-2030)
 - 8.6.4 U.S.
 - 8.6.5 Canada

9 EUROPE

- 9.1 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue (2019-2030)
- 9.2 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2030)

- 9.2.1 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2024)
- 9.2.2 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2025-2030)
- 9.3 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Type (2019-2030)
- 9.4 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2030)
 - 9.4.1 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2024)
 - 9.4.2 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2025-2030)
- 9.5 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Application (2019-2030)
- 9.6 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Country
 - 9.6.1 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019 VS 2023 VS 2030)
 - 9.6.2 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019-2024)
 - 9.6.3 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2025-2030)
 - 9.6.4 Germany
 - 9.6.5 France
 - 9.6.6 U.K.
 - 9.6.7 Italy
 - 9.6.8 Russia

10 CHINA

- 10.1 China Drugs for Herpes Labialis (Oral Herpes) Revenue (2019-2030)
- 10.2 China Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2030)
 - 10.2.1 China Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2024)
 - 10.2.2 China Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2025-2030)
- 10.3 China Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Type (2019-2030)
- 10.4 China Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2030)
 - 10.4.1 China Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2024)
 - 10.4.2 China Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2025-2030)

10.5 China Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Application (2019-2030)

11 ASIA (EXCLUDING CHINA)

11.1 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue (2019-2030)

11.2 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2030)

11.2.1 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2024)

11.2.2 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2025-2030)

11.3 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Type (2019-2030)

11.4 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2030)

11.4.1 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2024)

11.4.2 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2025-2030)

11.5 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Application (2019-2030)

11.6 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Country

11.6.1 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019 VS 2023 VS 2030)

11.6.2 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019-2024)

11.6.3 Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2025-2030)

11.6.4 Japan

11.6.5 South Korea

11.6.6 India

11.6.7 Australia

11.6.8 China Taiwan

11.6.9 Southeast Asia

12 MIDDLE EAST, AFRICA, LATIN AMERICA

12.1 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue (2019-2030)

12.2 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2030)

12.2.1 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2024)

12.2.2 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2025-2030)

12.3 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Type (2019-2030)

12.4 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2030)

12.4.1 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2024)

12.4.2 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2025-2030)

12.5 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Application (2019-2030)

12.6 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Country

12.6.1 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019 VS 2023 VS 2030)

12.6.2 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019-2024)

12.6.3 MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2025-2030)

12.6.4 Mexico

12.6.5 Brazil

12.6.6 Israel

12.6.7 Argentina

12.6.8 Colombia

12.6.9 Turkey

12.6.10 Saudi Arabia

12.6.11 UAE

13 CONCLUDING INSIGHTS

14 APPENDIX

14.1 Reasons for Doing This Study

14.2 Research Methodology

14.3 Research Process

14.4 Authors List of This Report

14.5 Data Source

14.5.1 Secondary Sources

14.5.2 Primary Sources

14.6 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate by Type (US\$ Million), 2019 VS 2023 VS 2030
- Table 1. Aciclovir Major Manufacturers
- Table 2. Valacyclovir Major Manufacturers
- Table 3. Famciclovir Major Manufacturers
- Table 4. Docosanol Major Manufacturers
- Table 5. Other Major Manufacturers
- Table 6. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate by Application (US\$ Million), 2019 VS 2023 VS 2030
- Table 7. External Use Major Manufacturers
- Table 8. Oral Major Manufacturers
- Table 9. Injection Major Manufacturers
- Table 10. Drugs for Herpes Labialis (Oral Herpes) Industry Trends
- Table 11. Drugs for Herpes Labialis (Oral Herpes) Industry Drivers
- Table 12. Drugs for Herpes Labialis (Oral Herpes) Industry Opportunities and Challenges
- Table 13. Drugs for Herpes Labialis (Oral Herpes) Industry Restraints
- Table 14. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (CAGR) by Region (US\$ Million): 2019 VS 2023 VS 2030
- Table 15. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2019-2024) & (US\$ Million)
- Table 16. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Region (2019-2024)
- Table 17. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2025-2030) & (US\$ Million)
- Table 18. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Region (2025-2030)
- Table 19. Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Players (US\$ Million) & (2019-2024)
- Table 20. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Players (2019-2024)
- Table 21. Global Drugs for Herpes Labialis (Oral Herpes) Key Players Ranking, 2022 VS 2023 VS 2024
- Table 22. Global Drugs for Herpes Labialis (Oral Herpes) Key Players Headquarters & Area Served

Table 23. Global Drugs for Herpes Labialis (Oral Herpes) Players, Product Type & Application

Table 24. Global Drugs for Herpes Labialis (Oral Herpes) Players Commercialization Time

Table 25. Global Players Market Concentration Ratio (CR5 and HHI)

Table 26. Global Drugs for Herpes Labialis (Oral Herpes) by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)

Table 27. Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Type 2019 VS 2023 VS 2030 (US\$ Million)

Table 28. Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2024) & (US\$ Million)

Table 29. Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2025-2030) & (US\$ Million)

Table 30. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Type (2019-2024) & (US\$ Million)

Table 31. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Type (2025-2030) & (US\$ Million)

Table 32. Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Application 2019 VS 2023 VS 2030 (US\$ Million)

Table 33. Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2024) & (US\$ Million)

Table 34. Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2025-2030) & (US\$ Million)

Table 35. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Application (2019-2024) & (US\$ Million)

Table 36. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Application (2025-2030) & (US\$ Million)

Table 37. GSK Company Information

Table 38. GSK Business Overview

Table 39. GSK Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 40. GSK Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 41. GSK Recent Development

Table 42. Novartis Company Information

Table 43. Novartis Business Overview

Table 44. Novartis Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 45. Novartis Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 46. Novartis Recent Development

Table 47. Teva Company Information

Table 48. Teva Business Overview

Table 49. Teva Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 50. Teva Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 51. Teva Recent Development

Table 52. Mylan Company Information

Table 53. Mylan Business Overview

Table 54. Mylan Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 55. Mylan Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 56. Mylan Recent Development

Table 57. Cadila Company Information

Table 58. Cadila Business Overview

Table 59. Cadila Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 60. Cadila Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 61. Cadila Recent Development

Table 62. Apotex Company Information

Table 63. Apotex Business Overview

Table 64. Apotex Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 65. Apotex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 66. Apotex Recent Development

Table 67. Daewoong Pharmaceutical Company Information

Table 68. Daewoong Pharmaceutical Business Overview

Table 69. Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 70. Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 71. Daewoong Pharmaceutical Recent Development

Table 72. Livzon Company Information

Table 73. Livzon Business Overview

Table 74. Livzon Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 75. Livzon Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 76. Livzon Recent Development

Table 77. Luoxin Company Information

Table 78. Luoxin Business Overview

Table 79. Luoxin Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 80. Luoxin Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 81. Luoxin Recent Development

Table 82. Med shine Company Information

Table 83. Med shine Business Overview

Table 84. Med shine Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 85. Med shine Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 86. Med shine Recent Development

Table 87. Bayer (Campho Phenique) Company Information

Table 88. Bayer (Campho Phenique) Business Overview

Table 89. Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 90. Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 91. Bayer (Campho Phenique) Recent Development

Table 92. Blistex Company Information

Table 93. Blistex Business Overview

Table 94. Blistex Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 95. Blistex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 96. Blistex Recent Development

Table 97. Kelun Company Information

Table 98. Kelun Business Overview

Table 99. Kelun Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 100. Kelun Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 101. Kelun Recent Development

Table 102. Hikma Company Information

Table 103. Hikma Business Overview

Table 104. Hikma Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 105. Hikma Drugs for Herpes Labialis (Oral Herpes) Product Portfolio

Table 106. Hikma Recent Development

Table 107. Haiwang Company Information

Table 108. Haiwang Business Overview

Table 109. Haiwang Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

- Table 110. Haiwang Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- Table 111. Haiwang Recent Development
- Table 112. Carmex Company Information
- Table 113. Carmex Business Overview
- Table 114. Carmex Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)
- Table 115. Carmex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- Table 116. Carmex Recent Development
- Table 117. Cipher Company Information
- Table 118. Cipher Business Overview
- Table 119. Cipher Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)
- Table 120. Cipher Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
- Table 121. Cipher Recent Development
- Table 122. North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2024) & (US\$ Million)
- Table 123. North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2024) & (US\$ Million)
- Table 124. North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)
- Table 125. North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019-2024) & (US\$ Million)
- Table 126. North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2025-2030) & (US\$ Million)
- Table 127. Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2024) & (US\$ Million)
- Table 128. Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2024) & (US\$ Million)
- Table 129. Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)
- Table 130. Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019-2024) & (US\$ Million)
- Table 131. Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2025-2030) & (US\$ Million)
- Table 132. China Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2024) & (US\$ Million)
- Table 133. China Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2024) & (US\$ Million)
- Table 134. Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2024)

& (US\$ Million)

Table 135. Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2024) & (US\$ Million)

Table 136. Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)

Table 137. Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019-2024) & (US\$ Million)

Table 138. Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2025-2030) & (US\$ Million)

Table 139. MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019-2024) & (US\$ Million)

Table 140. MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019-2024) & (US\$ Million)

Table 141. MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)

Table 142. MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2019-2024) & (US\$ Million)

Table 143. MEALA Drugs for Herpes Labialis (Oral Herpes) Revenue by Country (2025-2030) & (US\$ Million)

Table 144. Research Programs/Design for This Report

Table 145. Authors List of This Report

Table 146. Secondary Sources

Table 147. Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Drugs for Herpes Labialis (Oral Herpes) Product Picture

Figure 2. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate by Type (US\$ Million), 2019 VS 2023 VS 2030

Figure 3. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Share 2019 VS 2023 VS 2030

Figure 4. Aciclovir Picture

Figure 5. Valacyclovir Picture

Figure 6. Famciclovir Picture

Figure 7. Docosanol Picture

Figure 8. Other Picture

Figure 9. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate by Application (US\$ Million), 2019 VS 2023 VS 2030

Figure 10. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Share 2019 VS 2023 VS 2030

Figure 11. External Use Picture

Figure 12. Oral Picture

Figure 13. Injection Picture

Figure 14. Global Drugs for Herpes Labialis (Oral Herpes) Market Size (US\$ Million) & (2019-2030)

Figure 15. Global Drugs for Herpes Labialis (Oral Herpes) Market Size, (US\$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Region: 2019 VS 2023 VS 2030

Figure 17. Global Drugs for Herpes Labialis (Oral Herpes) Players Revenue Share Top 10 and Top 5 in 2023

Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 19. Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2019 VS 2023 VS 2030) & (US\$ Million)

Figure 20. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share 2019 VS 2023 VS 2030

Figure 21. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Type (2019-2030)

Figure 22. Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2019 VS 2023 VS 2030) & (US\$ Million)

Figure 23. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by

Application (2019 VS 2023 VS 2030)

Figure 24. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Application (2019-2030)

Figure 25. North America Drugs for Herpes Labialis (Oral Herpes) Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 26. North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2025-2030) & (US\$ Million)

Figure 27. North America Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Type (2019-2030)

Figure 28. North America Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2025-2030) & (US\$ Million)

Figure 29. North America Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Application (2019-2030)

Figure 30. North America Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Country (2019-2030)

Figure 31. United States Drugs for Herpes Labialis (Oral Herpes) Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 32. Canada Drugs for Herpes Labialis (Oral Herpes) Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 33. Europe Drugs for Herpes Labialis (Oral Herpes) Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 34. Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2025-2030) & (US\$ Million)

Figure 35. Europe Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Type (2019-2030)

Figure 36. Europe Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2025-2030) & (US\$ Million)

Figure 37. Europe Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Application (2019-2030)

Figure 38. Europe Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Country (2019-2030)

Figure 39. Germany Drugs for Herpes Labialis (Oral Herpes) Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 40. France Drugs for Herpes Labialis (Oral Herpes) Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 41. U.K. Drugs for Herpes Labialis (Oral Herpes) Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 42. Italy Drugs for Herpes Labialis (Oral Herpes) Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 43. Russia Drugs for Herpes Labialis (Oral Herpes) Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 44. Nordic Countries Drugs for Herpes Labialis (Oral Herpes) Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 45. China Drugs for Herpes Labialis (Oral Herpes) Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 46. China Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2025-2030) & (US\$ Million)

Figure 47. China Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Type (2019-2030)

Figure 48. China Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2025-2030) & (US\$ Million)

Figure 49. China Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Application (2019-2030)

Figure 50. Asia Drugs for Herpes Labialis (Oral Herpes) Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 51. Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Type (2025-2030) & (US\$ Million)

Figure 52. Asia Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Type (2019-2030)

Figure 53. Asia Drugs for Herpes Labialis (Oral Herpes) Revenue by Application (2025-2030) & (US\$ Million)

Figure 54. Asia Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Application (2019-2030)

Figure 55. Asia Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Country (2019-2030)

Figure 56. Japan Drugs for Herpes Labialis (Oral Herpes) R

I would like to order

Product name: Global Drugs for Herpes Labialis (Oral Herpes) Market Analysis and Forecast 2024-2030

Product link: <https://marketpublishers.com/r/GC1598F7BEEAEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC1598F7BEEAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970